REPRO-MED Systems ( (KRMD) ) has shared an announcement.
On April 3, 2025, Kenneth Miller resigned as Chief Commercial Officer of KORU Medical Systems to pursue a CEO role elsewhere. Rob Cannon, with extensive experience in healthcare sales, will temporarily lead the company’s commercial operations. Despite the leadership change, KORU Medical maintains its 2025 revenue guidance of $38.0-$39.0 million.
Spark’s Take on KRMD Stock
According to Spark, TipRanks’ AI Analyst, KRMD is a Neutral.
KRMD’s stock score reflects strong revenue growth and a positive outlook from the earnings call. However, significant profitability challenges, technical weakness, and a negative P/E ratio weigh down the overall score.
To see Spark’s full report on KRMD stock, click here.
More about REPRO-MED Systems
KORU Medical Systems, Inc. operates in the healthcare industry, focusing on providing medical systems and services. The company is known for its strategic commercial growth and has a market focus on specialty pharma and home infusion channels.
YTD Price Performance: -41.31%
Average Trading Volume: 202,814
Technical Sentiment Signal: Strong Buy
Current Market Cap: $104.8M
For an in-depth examination of KRMD stock, go to TipRanks’ Stock Analysis page.